View in EDS

Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.

Saved in:
Bibliographic Details
Title: Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.
Authors: Bensimon, Gilbert (AUTHOR), Leigh, P Nigel (AUTHOR), Tree, Timothy (AUTHOR), Malaspina, Andrea (AUTHOR), Payan, Christine AM (AUTHOR), Pham, Hang-Phuong (AUTHOR), Klaassen, Pieter (AUTHOR), Shaw, Pamela J (AUTHOR), Al Khleifat, Ahmad (AUTHOR), Amador, Maria D M (AUTHOR), Attarian, Shahram (AUTHOR), Bell, Simon M (AUTHOR), Beltran, Stéphane (AUTHOR), Bernard, Emilien (AUTHOR), Camu, William (AUTHOR), Corcia, Philippe (AUTHOR), Corvol, Jean-Christophe (AUTHOR), Couratier, Philippe (AUTHOR), Danel, Véronique (AUTHOR), Debs, Rabab (AUTHOR)
Source: Lancet. May2025, Vol. 405 Issue 10492, p1837-1850. 14p.
Subjects: Amyotrophic lateral sclerosis, Regulatory T cells, Subcutaneous injections, Random measures, Cerebrospinal fluid
Abstract: Amyotrophic lateral sclerosis (ALS) is a life-threatening disease characterised by progressive loss of motor neurons with few therapeutic options. The MIROCALS study tested the hypothesis that low-dose interleukin-2 (IL-2 LD) improves survival and function in ALS. In this randomised, double-blind, placebo-controlled trial, male and female riluzole-naive participants, with either a possible, laboratory-supported probable, probable, or definite ALS diagnosis (revised El Escorial criteria), aged 18–76 years, with symptom duration of 24 months or fewer, and slow vital capacity of 70% or more, underwent a riluzole-only 12–18 week run-in period before randomisation in a 1:1 ratio to either 2 million international units (MIU) IL-2 LD or placebo by subcutaneous injection daily for 5 days every 28 days over 18 months. The primary endpoint was survival at 640 days (21 months). Secondary outcomes included safety, ALS Functional Rating Scale-Revised (ALSFRS-R) score, and biomarker measurements including regulatory T-cells (Tregs), cerebrospinal fluid (CSF)-phosphorylated-neurofilament heavy-chain (CSF-pNFH), and plasma and CSF-chemokine ligand 2 (CCL2). The primary endpoint analysis used unadjusted log-rank and Cox's model adjusted analyses using pre-defined prognostic covariates to control for the disease and treatment response heterogeneity. The study was 80% powered to detect a two-fold decrease in the risk of death by the log-rank test in the intention-to-treat (ITT) population, including all randomly allocated participants. MIROCALS is registered with ClinicalTrials.gov (NCT03039673) and is complete. From June 19, 2017, to Oct 16, 2019, 304 participants were screened, of whom 220 (72%) met all criteria for random allocation after the 12-to-18-week run-in period on riluzole. 136 (62%) of participants were male and 84 participants (38%) were female. 25 (11%) of the 220 randomly allocated participants were defined as having possible ALS under El Escorial criteria. At the cutoff date there was no loss to follow-up, and all 220 patients who were randomly allocated were documented as either deceased (90 [41%]) or alive (130 [59%]), so all participants were included in the ITT and safety populations. The primary endpoint unadjusted analysis showed a non-significant 19% decrease in risk of death with IL-2 LD (hazard ratio 0·81 [95% CI 0·54–1·22], p=0·33), failing to demonstrate the expected two-fold decrease in risk of death. The analysis of the primary endpoint adjusted on prognostic covariates, all measured at time of random allocation, showed a significant decrease of the risk of death with IL-2 LD (0·32 [0·14–0·73], p=0·007), with a significant treatment by CSF-pNFH interaction (1·0003 [1·0001–1·0005], p=0·001). IL-2 LD was safe, and significantly increased Tregs and decreased plasma-CCL2 at all timepoints. Stratification on CSF-pNFH levels measured at random allocation showed that IL-2 LD was associated with a significant 48% decrease in risk of death (0·52 [0·30–0·89], p=0·016) in the 70% of the population with low (750–3700 pg/mL) CSF-pNFH levels, while in the 21% with high levels (>3700 pg/mL), there was no significant difference (1·37 [0·68–2·75], p=0·38). With this treatment schedule, IL-2 LD resulted in a non-significant reduction in mortality in the primary unadjusted analysis. However, the difference between the results of unadjusted and adjusted analyses of the primary endpoint emphasises the importance of controlling for disease heterogeneity in ALS randomised controlled trials. The decrease in risk of death achieved by IL-2 LD therapy in the trial population with low CSF-pNFH levels requires further investigation of the potential benefit of this therapy in ALS. European Commission H2020 Programme; French Health Ministry PHRC2014; and Motor Neurone Disease Association. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 185363207
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Bensimon%2C+Gilbert%22">Bensimon, Gilbert</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Leigh%2C+P+Nigel%22">Leigh, P Nigel</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tree%2C+Timothy%22">Tree, Timothy</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Malaspina%2C+Andrea%22">Malaspina, Andrea</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Payan%2C+Christine+AM%22">Payan, Christine AM</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pham%2C+Hang-Phuong%22">Pham, Hang-Phuong</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Klaassen%2C+Pieter%22">Klaassen, Pieter</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Shaw%2C+Pamela+J%22">Shaw, Pamela J</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Al+Khleifat%2C+Ahmad%22">Al Khleifat, Ahmad</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Amador%2C+Maria+D+M%22">Amador, Maria D M</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Attarian%2C+Shahram%22">Attarian, Shahram</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bell%2C+Simon+M%22">Bell, Simon M</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Beltran%2C+Stéphane%22">Beltran, Stéphane</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bernard%2C+Emilien%22">Bernard, Emilien</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Camu%2C+William%22">Camu, William</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Corcia%2C+Philippe%22">Corcia, Philippe</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Corvol%2C+Jean-Christophe%22">Corvol, Jean-Christophe</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Couratier%2C+Philippe%22">Couratier, Philippe</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Danel%2C+Véronique%22">Danel, Véronique</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Debs%2C+Rabab%22">Debs, Rabab</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. May2025, Vol. 405 Issue 10492, p1837-1850. 14p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Amyotrophic+lateral+sclerosis%22">Amyotrophic lateral sclerosis</searchLink><br /><searchLink fieldCode="DE" term="%22Regulatory+T+cells%22">Regulatory T cells</searchLink><br /><searchLink fieldCode="DE" term="%22Subcutaneous+injections%22">Subcutaneous injections</searchLink><br /><searchLink fieldCode="DE" term="%22Random+measures%22">Random measures</searchLink><br /><searchLink fieldCode="DE" term="%22Cerebrospinal+fluid%22">Cerebrospinal fluid</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Amyotrophic lateral sclerosis (ALS) is a life-threatening disease characterised by progressive loss of motor neurons with few therapeutic options. The MIROCALS study tested the hypothesis that low-dose interleukin-2 (IL-2 LD) improves survival and function in ALS. In this randomised, double-blind, placebo-controlled trial, male and female riluzole-naive participants, with either a possible, laboratory-supported probable, probable, or definite ALS diagnosis (revised El Escorial criteria), aged 18–76 years, with symptom duration of 24 months or fewer, and slow vital capacity of 70% or more, underwent a riluzole-only 12–18 week run-in period before randomisation in a 1:1 ratio to either 2 million international units (MIU) IL-2 LD or placebo by subcutaneous injection daily for 5 days every 28 days over 18 months. The primary endpoint was survival at 640 days (21 months). Secondary outcomes included safety, ALS Functional Rating Scale-Revised (ALSFRS-R) score, and biomarker measurements including regulatory T-cells (Tregs), cerebrospinal fluid (CSF)-phosphorylated-neurofilament heavy-chain (CSF-pNFH), and plasma and CSF-chemokine ligand 2 (CCL2). The primary endpoint analysis used unadjusted log-rank and Cox's model adjusted analyses using pre-defined prognostic covariates to control for the disease and treatment response heterogeneity. The study was 80% powered to detect a two-fold decrease in the risk of death by the log-rank test in the intention-to-treat (ITT) population, including all randomly allocated participants. MIROCALS is registered with ClinicalTrials.gov (NCT03039673) and is complete. From June 19, 2017, to Oct 16, 2019, 304 participants were screened, of whom 220 (72%) met all criteria for random allocation after the 12-to-18-week run-in period on riluzole. 136 (62%) of participants were male and 84 participants (38%) were female. 25 (11%) of the 220 randomly allocated participants were defined as having possible ALS under El Escorial criteria. At the cutoff date there was no loss to follow-up, and all 220 patients who were randomly allocated were documented as either deceased (90 [41%]) or alive (130 [59%]), so all participants were included in the ITT and safety populations. The primary endpoint unadjusted analysis showed a non-significant 19% decrease in risk of death with IL-2 LD (hazard ratio 0·81 [95% CI 0·54–1·22], p=0·33), failing to demonstrate the expected two-fold decrease in risk of death. The analysis of the primary endpoint adjusted on prognostic covariates, all measured at time of random allocation, showed a significant decrease of the risk of death with IL-2 LD (0·32 [0·14–0·73], p=0·007), with a significant treatment by CSF-pNFH interaction (1·0003 [1·0001–1·0005], p=0·001). IL-2 LD was safe, and significantly increased Tregs and decreased plasma-CCL2 at all timepoints. Stratification on CSF-pNFH levels measured at random allocation showed that IL-2 LD was associated with a significant 48% decrease in risk of death (0·52 [0·30–0·89], p=0·016) in the 70% of the population with low (750–3700 pg/mL) CSF-pNFH levels, while in the 21% with high levels (>3700 pg/mL), there was no significant difference (1·37 [0·68–2·75], p=0·38). With this treatment schedule, IL-2 LD resulted in a non-significant reduction in mortality in the primary unadjusted analysis. However, the difference between the results of unadjusted and adjusted analyses of the primary endpoint emphasises the importance of controlling for disease heterogeneity in ALS randomised controlled trials. The decrease in risk of death achieved by IL-2 LD therapy in the trial population with low CSF-pNFH levels requires further investigation of the potential benefit of this therapy in ALS. European Commission H2020 Programme; French Health Ministry PHRC2014; and Motor Neurone Disease Association. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=185363207
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(25)00262-4
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 14
        StartPage: 1837
    Subjects:
      – SubjectFull: Amyotrophic lateral sclerosis
        Type: general
      – SubjectFull: Regulatory T cells
        Type: general
      – SubjectFull: Subcutaneous injections
        Type: general
      – SubjectFull: Random measures
        Type: general
      – SubjectFull: Cerebrospinal fluid
        Type: general
    Titles:
      – TitleFull: Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Bensimon, Gilbert
      – PersonEntity:
          Name:
            NameFull: Leigh, P Nigel
      – PersonEntity:
          Name:
            NameFull: Tree, Timothy
      – PersonEntity:
          Name:
            NameFull: Malaspina, Andrea
      – PersonEntity:
          Name:
            NameFull: Payan, Christine AM
      – PersonEntity:
          Name:
            NameFull: Pham, Hang-Phuong
      – PersonEntity:
          Name:
            NameFull: Klaassen, Pieter
      – PersonEntity:
          Name:
            NameFull: Shaw, Pamela J
      – PersonEntity:
          Name:
            NameFull: Al Khleifat, Ahmad
      – PersonEntity:
          Name:
            NameFull: Amador, Maria D M
      – PersonEntity:
          Name:
            NameFull: Attarian, Shahram
      – PersonEntity:
          Name:
            NameFull: Bell, Simon M
      – PersonEntity:
          Name:
            NameFull: Beltran, Stéphane
      – PersonEntity:
          Name:
            NameFull: Bernard, Emilien
      – PersonEntity:
          Name:
            NameFull: Camu, William
      – PersonEntity:
          Name:
            NameFull: Corcia, Philippe
      – PersonEntity:
          Name:
            NameFull: Corvol, Jean-Christophe
      – PersonEntity:
          Name:
            NameFull: Couratier, Philippe
      – PersonEntity:
          Name:
            NameFull: Danel, Véronique
      – PersonEntity:
          Name:
            NameFull: Debs, Rabab
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 24
              M: 05
              Text: May2025
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 405
            – Type: issue
              Value: 10492
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1